Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781727 | 0.86 | KDM4E (0.38) | LPLLIPGADRA2AADRA2BADRA2C | |
| SCHEMBL12229096 | 0.80 | MAPT (0.41) | ADRA2AADRA2BADRA2CTRPA1CYP3A4 | |
| SCHEMBL3785277 | 0.79 | LPL (0.46) | LPLLIPGCYP3A4MAPTTRPV1 | |
| SCHEMBL3786914 | 0.77 | LPL (0.54) | LPLLIPGADRA2AADRA2BADRA2C | |
| SCHEMBL3789991 | 0.73 | CA2 (0.35) | LPLLIPGCA2CA1TSHR | |
| SCHEMBL3793129 | 0.69 | EGFR (0.40) | ADRA2AADRA2BADRA2CTSHRRECQL | |
| SCHEMBL21308005 | 0.69 | CA2 (0.35) | LPLLIPGCA2CA1TSHR | |
| SCHEMBL4596227 | 0.69 | LMNA (0.44) | ADRA2AADRA2BADRA2CCA2CA1 | |
| SCHEMBL3785827 | 0.68 | LPL (0.44) | LPLLIPGCA2CA1CYP3A4 | |
| SCHEMBL3781394 | 0.67 | ADRA2A (0.42) | LPLLIPGADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | LPL 3816/4885LIPG 3010/4885ADRA2A 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.